Abstracts tagged "methotrexate (MTX) and rheumatoid arthritis"

Abstract Number: 1322 • 2012 ACR/ARHP Annual Meeting
Coadministration of ASP015K, a Novel Janus Kinase Inhibitor with Methotrexate Demonstrates Tolerability and Lack of Pharmacokinetic Interactions in Patients with Rheumatoid Arthritis
Tong Zhu¹, Kazuo Oda², Udaya Valluri¹, Bogie Moore¹, Ying Cao¹, Vishala Chindalore³ and Bola Akinlade⁴, ¹Astellas Pharma Global Development, Inc., Northbrook, IL, ²Drug Metabolism Research Labs. Drug Discovery Research, Astellas Pharma Inc., Osaka, Japan, ³Pinnacle Research Group/Anniston Medical Clinic, Anniston, AL, ⁴Immunology Development, Astellas Pharma Global Development, Inc., Northbrook, IL
Background/Purpose: ASP015K is an oral Janus kinase (JAK) inhibitor with selectivity for JAK1/3 in development for treatment of rheumatoid arthritis (RA) and other autoimmune diseases.…
Abstract Number: 996 • 2012 ACR/ARHP Annual Meeting
Genetic Predictors of Methotrexate Efficacy and Toxicity in Early Rheumatoid Arthritis: Results From the Treatment of Early Aggressive Rheumatoid Arthritis Trial
Stella Aslibekyan¹, Elizabeth Brown², Richard J. Reynolds³, David T. Redden⁴, Sarah L. Morgan⁵, Joseph Baggott¹, Jin Sha¹, Larry W. Moreland⁶, James R. O'Dell⁷, Jeffrey R. Curtis⁸, S. Louis Bridges Jr.⁹ and Donna K. Arnett¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Univ of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama Birmingham, Birmingham, AL, ⁶Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Dept of Internal Medicine, Univ of Nebraska Med Ctr, Omaha, NE, ⁸Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL, ⁹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) has emerged as first-line therapy for early moderate to severe rheumatoid arthritis (RA), but individual variation in treatment efficacy and toxicity remains…
Abstract Number: 997 • 2012 ACR/ARHP Annual Meeting
Evidence of Novel Genetic Predictors of Methotrexate Efficacy in Rheumatoid Arthritis
Stella Aslibekyan¹, Maria I. Danila², Jin Sha¹, David T. Redden³, Richard J. Reynolds⁴, Elizabeth Brown⁵, Laura B. Hughes⁶, Molly S. Bray¹, Sarah L. Morgan⁷, Larry W. Moreland⁸, James R. O'Dell⁹, Jeffrey R. Curtis¹⁰, Robert P. Kimberly¹¹, Lindsey A. Criswell¹², Robert M. Plenge¹³, S. Louis Bridges Jr.¹⁴ and Donna K. Arnett¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Med/Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ³Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Univ of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, ⁶Med Div of Clin Imm & Rheum, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama Birmingham, Birmingham, AL, ⁸Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹Dept of Internal Medicine, Univ of Nebraska Med Ctr, Omaha, NE, ¹⁰Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL, ¹¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹²Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ¹³Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ¹⁴Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX), a disease-modifying anti-rheumatic drug used as first-line therapy in rheumatoid arthritis (RA), is characterized by considerable heterogeneity in individual treatment response. We…
Abstract Number: 774 • 2012 ACR/ARHP Annual Meeting
A CD4+ T-Cell Gene Expression Signature Predicts Drug Survival On Methotrexate Monotherapy in Early Rheumatoid Arthritis
Arthur G. Pratt¹, Philip M. Brown², Simon J. Cockell³, Gillian Wilson⁴ and John D. Isaacs¹, ¹Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom, ³Bioinformatics Unit, Newcastle University, Newcastle-upon-Tyne, United Kingdom, ⁴Directorate of Musculoskeletal Medicine, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom
Background/Purpose: The mechanism of action of methotrexate (MTX) in the management of rheumatoid arthritis (RA) remains incompletely understood. It is nonetheless capable of inducing clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].